China is gearing up for a new wave of home‑grown medicines that can compete on the world stage. The government’s first “Major New Drug Creation” program, launched in 2008, helped turn the country from a copier of foreign drugs into an innovator, delivering 84 first‑in‑class drugs and 41 new traditional Chinese medicines. Notable successes include Zanubrutinib, the first Chinese‑made cancer drug to break into the U.S. market and generate $1.3 billion in sales. Despite these wins, experts say China still lags in true originality. The nation produces far fewer drugs that target new biological pathways than the United States or Europe, and many research teams chase the same popular targets, leaving deadly cancers like pancreatic cancer under‑served. Fragmented collaboration among labs, universities, and companies also slows progress. To fix this, a fresh “National Science and Technology Major Project for Innovative Drug R&D” was unveiled in July, backed by 1.75 billion yuan. The plan pivots from sheer volume to quality, emphasizing four key shifts: building core drug‑creation capabilities, investing in upstream basic research, prioritizing truly original medicines, and aligning projects with China’s most pressing health needs—chronic and infectious diseases, plus pediatric, rare, and special‑scenario conditions. The goal is a sustainable, world‑leading drug pipeline that addresses both domestic gaps and global markets.
Read moreA wave of new research is reshaping how we think about health and disease. First, scientists discovered that low cholesterol levels in pregnant mothers can disrupt Hedgehog signaling, raising the risk of congenital heart defects in babies; a simple cholesterol supplement during pregnancy might cut that risk. In a massive genetics effort, Chinese researchers charted a detailed map of polycystic ovary syndrome, pinpointing 94 genetic hotspots—73 of them brand‑new—and built a risk‑score model that could one day guide personalized care. At Tianjin Medical University, a team identified the FPR1 pathway as a driver of brain inflammation in multiple sclerosis, opening a promising therapeutic target. Meanwhile, cancer biologists revealed why chemotherapy can push breast‑cancer cells into a dormant, drug‑resistant state: the treatment sparks the WNT pathway, silencing the MYC gene and halting cell growth. In neuroscience, Henan University uncovered a molecular “switch” that lets oligodendrocyte precursor cells keep proliferating even when glucose is scarce, ensuring proper myelin formation and repair. Finally, a University of Melbourne trial showed that a 12‑week, unsupervised online Tai Chi program dramatically eases knee‑joint pain and improves function for osteoarthritis sufferers, with over 70 % reporting noticeable relief. Together, these findings highlight how simple lifestyle tweaks, cutting‑edge genetics, and novel drug targets are converging to improve human health.
Read more